Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Accrued rebates and chargebacks liability by Year
Accrued rebates and chargebacks liability (Balance Sheet, $M) ($M)
Gilead Sciences Accrued rebates and chargebacks liability: $4,337M in FY2025, up 11.4% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-Q (filed 2026-08-06) ↗
Reported in Form 10-Q / 10-K Accrued Liabilities & Critical Accounting Estimates.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up accrued rebates and chargebacks liability
- Total gross-to-net (GTN) deductions ($M)19,953 · FY2025
- Gross-to-net deductions as % of gross product sales (%)41.0% · FY2025
- Rebates & chargebacks rollforward — Beginning balance ($M)4,646 · FY2025
- Rebates & chargebacks rollforward — Total provision (decrease to product sales, $M)17,503 · FY2025
- Rebates & chargebacks rollforward — Total payments ($M)16,967 · FY2025
- Rebates & chargebacks rollforward — Ending balance ($M)5,181 · FY2025
Cite this data
StockData. (2026). Gilead Sciences Accrued rebates and chargebacks liability ($M), annual FY2013–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/gtn-rebates-liab
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.